Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeljanz in Moderate to Severe Alopecia Areata
NCT02299297Phase 2Completed
- Sponsor
- Columbia University
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tofacitinib oral solution in alopecia areata, sponsored by Columbia University. Primary endpoint: Total Number of Responders at 72 weeks. Started Jan 2015; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT02299297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02299297.